𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995–2001

✍ Scribed by N. Hasham-Jiwa; Y. Kasakura; J. A. Ajani

Book ID
106285579
Publisher
Springer
Year
2002
Tongue
English
Weight
60 KB
Volume
7
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The management of ductal carcinoma in si
The management of ductal carcinoma in situ in North America and Europe : Results of a survey
✍ Elizabeth Ceilley; Reshma Jagsi; Saveli Goldberg; Lisa Kachnic; Simon Powell; Al 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

## Abstract ## BACKGROUND The goal of the current study was to understand and document contemporary treatment approaches in the management of ductal carcinoma in situ (DCIS). ## METHODS An original questionnaire was designed to assess radiation oncologists' management of breast carcinoma, includ

Recent advances in surgical treatment ha
Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma
✍ Eigo Otsuji; Toshiharu Yamaguchi; Kiyoshi Sawai; Akeo Hagiwara; Hiroki Taniguchi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

## RESULTS. Postoperative survival was significantly improved in the later groups for patients with Stage I, II, III, and IV disease. A multivariate analysis of prognostic factors revealed that the time period during which the gastrectomy was performed was an independent predictor of survival. ##

Safety and efficacy results of the advan
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
✍ Walter M. Stadler; Robert A. Figlin; David F. McDermott; Janice P. Dutcher; Jenn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract ## BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. ## METHODS: In this nonrandomized, open‐label expanded access program, 2504 patients from the United St